CNTX-4975
-
Extremities
Centrexion Therapeutics to Present Data on CNTX-4975 from the Treatment of Knee Osteoarthritis Pain at IX SIMPAR-ISURA
March 23, 2017 BOSTON–(BUSINESS WIRE)–Centrexion Therapeutics, a company focused on advancing the treatment of chronic pain with one of the largest exclusively pain-focused…
Read More » -
Biologics
Centrexion Therapeutics Announces Highly Statistically Significant Topline Results from Phase 2b Study of CNTX-4975 in Patients with Knee Osteoarthritis Pain
Boston – December 13, 2016 – Centrexion Therapeutics, a company focused on advancing the treatment of chronic pain with one of the largest…
Read More »